Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM) Clinical Trial

Official title:
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Status Completed

Clinical Trial Summary

This was a single-arm, multicenter Phase 2 study in Chinese participants with relapsed or refractory Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the Seventh International Workshop on Waldenström's Macroglobulinemia (IWWM). The study comprised an initial screening phase (up to 28 days), a single-arm treatment phase, and a follow-up phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Waldenstrom Macroglobulinemia
Waldenström's Macroglobulinemia (WM)

Clinical Trial Details

NCT number	NCT03332173
Study type	Interventional
Source	BeiGene
Contact
Status	Completed
Phase	Phase 2
Start date	August 31, 2017
Completion date	January 11, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06043011` - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
	Not yet recruiting	`NCT06441214` - Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.